(Q34267775)

1 August 2017

1 reference

title

Biologic and therapeutic role of HER2 in cancer (English)

1 reference

1 August 2017

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206779

18 March 2024

author name string

Sylvie Ménard

1

1 reference

1 August 2017

Serenella Marja Pupa

2

1 reference

1 August 2017

Manuela Campiglio

3

1 reference

1 August 2017

Elda Tagliabue

4

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

1 August 2017

29 September 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14528282

full work available at URL

18 March 2024

https://www.nature.com/articles/1206779.pdf

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14528282

https://www.nature.com/articles/1206779.pdf

18 March 2024

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206779

https://www.nature.com/articles/1206779

18 March 2024

1 reference

DOI

https://api.crossref.org/works/10.1038/SJ.ONC.1206779

18 March 2024

1 reference

1 August 2017

volume

22

1 reference

1 August 2017

issue

42

1 reference

1 August 2017

page(s)

6570-6578

1 reference

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Colocalization of the p185HER2 oncoprotein and integrin alpha 6 beta 4 in Calu-3 lung carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Humanization of an anti-p185HER2 antibody for human cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Antitumor Efficacy of Adenocarcinoma Cells Engineered to Produce Interleukin 12 (IL-12) or Other Cytokines Compared With Exogenous IL-12

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Cancer cell motility--on the road from c-erbB-2 receptor steered signaling to actin reorganization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Prophylactic cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Cooperative signaling between alpha(6)beta(4) integrin and ErbB-2 receptor is required to promote phosphatidylinositol 3-kinase-dependent invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Cellular immunity to the Her-2/neu protooncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

In vivo natural killer cell activities revealed by natural killer cell-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Antitumor vaccines: is it possible to prevent a tumor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Prognostic and predictive value of HER2/neu oncogene in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Role of HER2 gene overexpression in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Post-transcriptional control regulates transforming growth factor alpha in the human carcinoma KB cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Making and breaking tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

HER-2/neu expression in germ cell tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Laminin activates the p185HER2 oncoprotein and mediates growth inhibition of breast carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Role of proliferation in HER2 status predicted response to doxorubicin.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Role of p53 in HER2-induced proliferation or apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Immunotherapy I: Cyclosine gene transfer strategies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Cell biology of lymphatic metastasis. The potential role of c-erbB oncogene signalling.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Designing HER2 vaccines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Epidermal growth factor receptor family in lung cancer and premalignancy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Bidirectional interactions between the estrogen receptor and the cerbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Molecular mechanisms underlying ErbB2/HER2 action in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Clinical cancer vaccine trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Requirement for neuregulin receptor erbB2 in neural and cardiac development

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

MCF-7 breast cancer cells overexpressing transfectedc-erbB-2 have anin vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivityin vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

HER2 as a prognostic factor in breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Antiestrogens and the reduction in circulating cholesterol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Multiple essential functions of neuregulin in development

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

The influence of surgical trauma on experimental metastasis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Cytokine gene therapy: hopes and pitfalls

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Heregulin induces tyrosine phosphorylation of HER4/p180erbB4

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Prognostic significance of her-2/neu expression in breast cancer and its relationship to other prognostic factors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Prevention of spontaneous mammary adenocarcinoma in HER-2/neu transgenic mice by foreign DNA

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

A strain-independent postnatal neurodegeneration in mice lacking the EGF receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

The early relapse of premenopausal patients after surgery for node-positive breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

1 reference

7 January 2021

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Gene expression profiling predicts clinical outcome of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Absence of evidence for HER2 amplification in nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Novel targets of Akt, p21(Cipl/WAF1), and MDM2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206779

7 January 2021

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

1039632912

0 references

1 reference